Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$42.12 USD
-0.17 (-0.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $42.09 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Crinetics Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 559 | 334 | 334 | 171 | 118 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 16 | 11 | 11 | 7 | 5 |
Total Current Assets | 574 | 345 | 345 | 177 | 123 |
Net Property & Equipment | 11 | 4 | 3 | 3 | 4 |
Investments & Advances | 0 | 0 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 2 | 1 | 1 | 1 |
Total Assets | 635 | 352 | 351 | 183 | 130 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 23 | 15 | 8 | 6 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 9 | 7 | 4 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 3 | 1 | 1 | 1 |
Total Current Liabilities | 44 | 28 | 16 | 10 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 6 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 96 | 36 | 19 | 15 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1,192 | 759 | 608 | 337 | 211 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -654 | -439 | -275 | -168 | -94 |
Other Equity | 1 | -4 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 539 | 316 | 332 | 169 | 117 |
Total Liabilities & Shareholder's Equity | 635 | 352 | 351 | 183 | 130 |
Total Common Equity | 539 | 316 | 332 | 169 | 117 |
Shares Outstanding | 66.80 | 53.70 | 47.50 | 32.90 | 24.20 |
Book Value Per Share | 8.07 | 5.89 | 6.99 | 5.13 | 4.84 |
Fiscal Year End for Crinetics Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 559 | 555 | 265 | 296 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 16 | 21 | 20 | 9 |
Total Current Assets | NA | 574 | 576 | 285 | 305 |
Net Property & Equipment | NA | 11 | 10 | 3 | 3 |
Investments & Advances | NA | 0 | 5 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 3 | 3 | 4 | 4 |
Total Assets | NA | 635 | 642 | 293 | 314 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 23 | 22 | 21 | 16 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 15 | 13 | 9 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 2 | 2 | 2 |
Total Current Liabilities | NA | 44 | 40 | 33 | 26 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 5 | 5 | 5 | 6 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 96 | 94 | 39 | 34 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1,192 | 1,142 | 792 | 768 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | -654 | -594 | -536 | -485 |
Other Equity | NA | 1 | -1 | -2 | -3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 539 | 548 | 254 | 280 |
Total Liabilities & Shareholder's Equity | NA | 635 | 642 | 293 | 314 |
Total Common Equity | 0 | 539 | 548 | 254 | 280 |
Shares Outstanding | 69.60 | 66.80 | 54.60 | 54.00 | 54.00 |
Book Value Per Share | 0.00 | 8.07 | 10.03 | 4.71 | 5.19 |